Breaking News Instant updates and real-time market news.

BIIB

Biogen

$236.08

4.89 (2.12%)

, NVS

Novartis

$82.79

0.17 (0.21%)

08:53
05/07/19
05/07
08:53
05/07/19
08:53

Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley

Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.

BIIB

Biogen

$236.08

4.89 (2.12%)

NVS

Novartis

$82.79

0.17 (0.21%)

IONS

Ionis Pharmaceuticals

$72.69

-0.8 (-1.09%)

RGNX

Regenxbio

$52.36

0.77 (1.49%)

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 14

    May

  • 23

    May

  • 29

    May

  • 31

    May

  • 31

    May

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

BIIB Biogen
$236.08

4.89 (2.12%)

04/10/19
RAJA
04/10/19
INITIATION
RAJA
Market Perform
Biogen resumed with a Market Perform at Raymond James
Raymond James analyst Steven Seedhouse resumed coverage of Biogen with a Market Perform rating, stating that the company's remaining business following the failure of aducanumab "appears a little fragile" and faces "existential risk" in some cases, such as the Tecfidera IPR decision due in 2020. Near-term pipeline readouts, including the nearest readouts on Vumerity and BIIB067, don't seem high-impact enough to reverse sentiment, Seedhouse tells investors.
04/11/19
BERN
04/11/19
INITIATION
Target $48
BERN
Outperform
PTC Therapeutics initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen started coverage on PTC Therapeutics (PTCT) with an Outperform rating and a $48 price target, given his positive view on the commercial potential of risdiplam in SMA. The analyst believes that there will still be a substantial market opportunity for non-gene therapy drugs after approval, and thinks risdiplam's oral dosing will be a substantial advantage over Biogen (BIIB) Spinraza's intrathecal administration. If risdiplam is safe and comparably efficacious to Spinraza, Chen forecasts potential for $2.5B in revenues by 2030.
04/24/19
PIPR
04/24/19
NO CHANGE
Target $280
PIPR
Overweight
Piper still recommends Biogen despite 'not the best' quarter
Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares following this morning's Q1 results. While the quarter was "not the best," near-term catalysts warrant staying involved, including clinical updates for BIIB067 and BIIB098 head-to-head data versus Tecfidera expected in mid-2019, Raymond tells investors in a research note. Ahead of a Q4 regulatory decision for BIIB098, the analyst continues to like the upside potential for the pipeline. He keeps an Overweight rating on Biogen with a $280 price target.
05/02/19
PIPR
05/02/19
NO CHANGE
Target $280
PIPR
Overweight
Owning Biogen shares here 'makes a lot of sense,' says Piper Jaffray
Owning Biogen (BIIB) shares at these levels "makes a lot of sense," Piper Jaffray analyst Christopher Raymond tells investors in a research note after hosting management meetings with investors. With valuation and sentiment near all-time lows, the company needs only a few things to go right in order for the stock to start working again, says the analyst. He believes a number of near term catalysts, namely a settlement with Mylan (MYL) over Tecfidera and positive pipeline updates, could "meaningfully change the narrative" on Biogen shares. Raymond keeps an Overweight rating on the name with a $280 price target.
NVS Novartis
$82.79

0.17 (0.21%)

04/25/19
04/25/19
UPGRADE

Buy
Novartis upgraded to Buy from Neutral at Guggenheim
As previously reported, Guggenheim analyst Seamus Fernandez upgraded Novartis to Buy with a price target of CHF95, saying he is more confient that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. The analyst notes that investors have an "attractive opportunity" given the company's "structural shift in operating margins driven by transformational SMA gene therapy, Zolgensma, a best-case Mayzent label in MS, and several near-term pipeline catalysts."
04/25/19
04/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at UBS with analyst Eric Sheridan saying while 2019 remains a year of transition, Facebook management has now produced multiple quarters of better than expected revenue and earnings. 2. American Express (AXP) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Betsy Graseck saying she believes its strong revenue growth remains intact given its record growth in proprietary cards, strong contribution from Millennials, fee-based products and its strong loan and transactional growth. 3. Novartis (NVS) upgraded to Buy from Neutral at Guggenheim with analyst Seamus Fernandez saying he is more confident that the company "can deliver several years of mid-single digit operating profit and EPS growth" through 2024. 4. Sirius XM (SIRI) upgraded to Buy from Hold at Pivotal Research with analyst Jeffrey Wlodarczak saying yesterday's post-earnings selloff was overdone as investors overreacted to slightly lower than expected new car installations and modestly lower than expected self-pay net subscriber additions. 5. General Dynamics (GD) upgraded to Neutral from Underweight at JPMorgan with analyst Seth Seifman saying General Dynamics has underperformed the market by~21% since the start of 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/19
WELS
05/01/19
NO CHANGE
Target $18
WELS
Market Perform
Teva shares reflect much of bad news, says Wells Fargo
Wells Fargo analyst David Morris kept his Market Perform rating and $18 price target on Teva (TEVA) ahead of its Q1 earnings tomorrow, saying investors have "low expectations" for the quarter after "weak-ish" Sandoz results from Novartis (NVS). The analyst also points to IQVIA (IQV) sales and prescriptions data indicating that Teva generic sales were down 12% in March, 10% in February, and 13% in January, though the decline are "much smaller" than seen in U.S. generics during 2018. Morris further expects Teva to address the risk of opioid litigation that became a concern during the quarter in its earnings call.
05/02/19
FBCO
05/02/19
INITIATION
Target $66
FBCO
Outperform
Alcon initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic started coverage of Alcon (ALC) with an Outperform rating and a $66 price target. Recently spun off from parent Novartis (NVS), Alcon is now positioned to deliver improving growth and margins, the analyst contends. Miksic believes the key to the Alcon investment case is the opportunity to increase revenue growth and margins through expanded market share and its leadership positions in cataract, retinal surgery, contact lenses and consumer eye care.
IONS Ionis Pharmaceuticals
$72.69

-0.8 (-1.09%)

04/17/19
WELS
04/17/19
NO CHANGE
WELS
Wells says Ionis weakness on Roche Huntington's update a buying opportunity
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
05/07/19
PIPR
05/07/19
NO CHANGE
Target $142
PIPR
Overweight
Piper more confident in estimates for Alnylam's Onpattro after doctor survey
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $142 price target after surveying 16 physicians treating 490 hereditary transthyretin amyloidosis patients with polyneuropathy. Doctors have a "clear preference" for Alnylam's Onpattro over Onpattro and Ionis Pharmaceuticals' (IONS) Tegsedi, with efficacy, safety, and experience being cited, Tenthoff tells investors in a research note. Roughly two-thirds of existing and new gene silencer patients are prescribed Onpattro, says the analyst. Based on the survey results, the analyst is increasingly confident in his 2019 Onpattro sales estimates of $127M.
RGNX Regenxbio
$52.36

0.77 (1.49%)

02/05/19
02/05/19
UPGRADE
Target $94

Strong Buy
Raymond James upgrades Regenxbio to Strong Buy after pullback
As previously reported, Raymond James analyst Reni Benjamin upgraded Regenxbio to Strong Buy from Outperform, stating that his recent talks with management gave him added information on RGX-314 in patients with wet age-related macular degeneration and an update on the company's other gene therapy programs. He believes the recent pullback in shares presents an attractive opportunity "for risk-tolerant investors" given that the company has four wholly owned assets "poised to deliver data in 2019," Benjamin said. He has a $94 price target on Regenxbio shares.
02/05/19
02/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Covanta (CVA) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying he expects near-term U.K. project pipeline catalysts to highlight the company's medium-to-long term growth potential. 2. Booking Holdings (BKNG) upgraded to Buy from Hold at Deutsche Bank with analyst Lloyd Walmsley saying Booking's room night growth can accelerate in 2019 as the company "leans back into marketing channels," and this can drive multiple expansion. 3. Regenxbio (RGNX) upgraded to Strong Buy from Outperform at Raymond James with analyst Reni Benjamin saying his recent talks with management gave him added information on RGX-314 in patients with wet age-related macular degeneration and an update on the company's other gene therapy programs. 4. Legg Mason (LM) upgraded to Buy from Neutral at Citi. 5. Nine Energy Services (NINE) upgraded to Buy from Hold at Tudor Pickering. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/25/19
EVER
02/25/19
UPGRADE
EVER
Outperform
Regenxbio upgraded to Outperform from In Line at Evercore ISI
02/25/19
02/25/19
UPGRADE
Target $79

Outperform
Regenxbio upgraded to Outperform ahead of catalysts at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer upgraded Regenxbio (RGNX) to Outperform from In Line, with a $79 price target, ahead of some important catalysts this year. While not without risk and important unanswered question, the analyst sees optionality that skews more to the upside. Further, Schimmer believes the Wall Street Journal article suggesting Roche (RHHBY) may bid for Spark Therapeutics (ONCE) will likely lift all gene therapy company shares, including Regenxbio.

TODAY'S FREE FLY STORIES

BCYC

Bicycle Therapeutics

$0.00

(0.00%)

21:58
05/22/19
05/22
21:58
05/22/19
21:58
Syndicate
Bicycle Therapeutics 4.333M share IPO priced at $14.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

21:36
05/22/19
05/22
21:36
05/22/19
21:36
Syndicate
IDEAYA Biosciences 5M share IPO priced at $10.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

MDT

Medtronic

$89.02

1.22 (1.39%)

, HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

20:25
05/22/19
05/22
20:25
05/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$89.02

1.22 (1.39%)

HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

BBY

Best Buy

$69.26

-0.68 (-0.97%)

BJ

BJ's Wholesale

$26.50

0.94 (3.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 11

    Jun

  • 20

    Jun

HFC

HollyFrontier

$42.69

-1.45 (-3.29%)

20:19
05/22/19
05/22
20:19
05/22/19
20:19
Periodicals
Breaking Periodicals news story on HollyFrontier »

HollyFrontier to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$33.43

-0.58 (-1.71%)

, MSFT

Microsoft

$127.67

0.77 (0.61%)

20:04
05/22/19
05/22
20:04
05/22/19
20:04
Recommendations
Pluralsight, Microsoft analyst commentary at First Analysis »

Meetings with Pluralsight…

PS

Pluralsight

$33.43

-0.58 (-1.71%)

MSFT

Microsoft

$127.67

0.77 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

GTE

Gran Tierra

$2.09

-0.03 (-1.42%)

19:28
05/22/19
05/22
19:28
05/22/19
19:28
Hot Stocks
Gran Tierra confirms award of 3 Ecuador blocks with 140K acre total area »

Gran Tierra announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$80.47

0.44 (0.55%)

19:10
05/22/19
05/22
19:10
05/22/19
19:10
Hot Stocks
Progressive's Sieger sells 7,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$157.60

1.83 (1.17%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Hot Stocks
Salesforce Ventures launches $125M Europe Trailblazer Fund »

Salesforce announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 06

    Jun

  • 23

    Jun

MRCY

Mercury Systems

$70.96

0.08 (0.11%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Syndicate
Mercury Systems 6M share Secondary priced at $69.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 23

    May

RNG

RingCentral

$122.58

0.14 (0.11%)

18:57
05/22/19
05/22
18:57
05/22/19
18:57
Hot Stocks
RingCentral CEO: We have an all in one solution for business communications »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 13

    Nov

LB

L Brands

$24.29

1.605 (7.08%)

, VIPS

Vipshop

$7.75

0.095 (1.24%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: L…

LB

L Brands

$24.29

1.605 (7.08%)

VIPS

Vipshop

$7.75

0.095 (1.24%)

CPRT

Copart

$64.99

-0.91 (-1.38%)

CTRP

Ctrip

$37.78

-0.09 (-0.24%)

SNPS

Synopsys

$115.10

-0.63 (-0.54%)

AVP

Avon Products

$4.07

0.875 (27.39%)

GILD

Gilead

$67.25

0.73 (1.10%)

IOVA

Iovance Biotherapeutics

$17.71

1.5 (9.25%)

AMGN

Amgen

$173.23

3.61 (2.13%)

NTAP

NetApp

$62.58

-7.43 (-10.61%)

SCVL

Shoe Carnival

$29.65

-2.6 (-8.06%)

HTHT

Huazhu Group

$34.41

-0.47 (-1.35%)

SBLK

Star Bulk Carriers

$8.13

-0.13 (-1.57%)

ONVO

Organovo

$0.78

-0.158 (-16.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

HMC

Honda

$25.54

-0.17 (-0.66%)

, TKTDY

Takata

$0.00

(0.00%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Honda to recall about 19,000 vehicles in the U.S. over faulty inflator kits »

Honda (HMC) will…

HMC

Honda

$25.54

-0.17 (-0.66%)

TKTDY

Takata

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

18:39
05/22/19
05/22
18:39
05/22/19
18:39
Periodicals
Breaking Periodicals news story on Daiichi Sankyo »

Daiichi Sankyo in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SPOT

Spotify

$127.10

-5.06 (-3.83%)

18:27
05/22/19
05/22
18:27
05/22/19
18:27
Periodicals
Spotify resets some users' passwords over 'suspicious activity,' TechCrunch says »

Spotify has informed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXX

Idexx Laboratories

$250.45

1.24 (0.50%)

18:20
05/22/19
05/22
18:20
05/22/19
18:20
Hot Stocks
Idexx Laboratories CEO: We're at the beginning of our runway for growth »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

OMC

Omnicom

$79.79

-0.3 (-0.37%)

18:15
05/22/19
05/22
18:15
05/22/19
18:15
Hot Stocks
Omnicom CEO sells 60.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.74

0.04 (0.11%)

18:12
05/22/19
05/22
18:12
05/22/19
18:12
Hot Stocks
Boston Scientific initiates trial of WATCHMAN FLX appendage closure platform »

Boston Scientific has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 26

    Jun

  • 13

    Nov

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:03
05/22/19
05/22
18:03
05/22/19
18:03
Hot Stocks
Ctrip reports Q1 gross margin 79% vs. 82% a year ago »

Remained consistent with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:02
05/22/19
05/22
18:02
05/22/19
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Earnings
Ctrip reports Q1 adjusted EPS 44c, consensus 24c »

Reports Q1 revenue $1.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CE

Celanese

$100.10

-0.18 (-0.18%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Hot Stocks
Celanese announces acetyls product price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$54.64

-0.25 (-0.46%)

17:57
05/22/19
05/22
17:57
05/22/19
17:57
Hot Stocks
Dentsply Sirona CFO Alexos to leave company in connection with relocation »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

SIM

Grupo Simec

$9.23

(0.00%)

17:55
05/22/19
05/22
17:55
05/22/19
17:55
Hot Stocks
Grupo Simec receives noncompliance notification from NYSE »

Grupo Simec announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$64.78

-1.12 (-1.70%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Earnings
Copart reports Q3 adjusted EPS 66c, consensus 62c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

NVS

Novartis

$83.94

1.555 (1.89%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Periodicals
Novartis CEO sees Zolgensma price 'far lower' than $4M-$5M range, Reuters says »

Novartis CEO Vas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.